Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1037 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Valeant Pharma to take over Afexa

As per the terms of the deal, holders of Afexa common shares will receive C$0.71 in cash per common share. Valeant chairman and CEO Michael Pearson said Afexa’s

Toyama, Eisai file MAA for anti-rheumatic drug

T-614 is a novel disease modifying anti-rheumatic drug (DMARD) originally discovered by Toyama Chemical. Toyama Chemical and Eisai are jointly developing T-614 under a co-development and licensing deal

inVentiv Q2 net revenue rises

The company has posted a net loss of $3.31m for the second quarter of 2011, compared to $9.94m for the same period in 2010. inVentiv’s operating income was